Lacasa 50/Lacasa 100/Lacasa 150

Lacosamide

Monotherapy or adjunctive therapy of partial-onset seizures. Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients ≥4 yr.

Partial-onset seizures (monotherapy or adjunctive therapy) & primary generalized tonic-clonic seizures (adjunctive therapy) Adult ≥17 yr Initially 100 mg bid (200 mg daily) as monotherapy or 50 mg bid (100 mg daily) as adjunctive therapy. Alternatively, 200 mg single loading dose, followed approx 12 hr later by 100 mg bid (200 mg daily). Titration regimen: Increase by 50 mg bid (100 mg daily) every wk. Maintenance: 150-200 mg bid (300-400 mg daily) as monotherapy or 100-200 mg bid (200-400 mg daily) as adjunctive therapy. Ped weighing ≥50 kg Initially 50 mg bid (100 mg daily). Titration regimen: Increase by 50 mg bid (100 mg daily) every wk. Maintenance: 150-200 mg bid (300-400 mg daily) as monotherapy or 100-200 mg bid (200-400 mg daily) as adjunctive therapy; 30-<50 kg Initially 1 mg/kg bid (2 mg/kg daily). Titration regimen: Increase by 1 mg/kg bid (2 mg/kg daily) every wk. Maintenance: 2-4 mg/kg bid (4-8 mg/kg daily); 11-<30 kg 1 mg/kg bid (2 mg/kg daily). Titration regimen: Increase by 1 mg/kg bid (2 mg/kg daily) every wk. Maintenance: 3-6 mg/kg bid (6-12 mg/kg daily). Mild or moderate hepatic impairment Reduction of 25% of the max dose. Severe renal impairment or ESRD Reduction of 25% of the max dose. Hemodialysis Dose supplementation of up to 50% following a 4-hr hemodialysis treatment.

May be taken with or without food.

Hypersensitivity. Known 2nd- or 3rd-degree AV block.

Suicidal ideation & behavior. Patients w/ known conduction problems or severe cardiac disease (eg, history of MI or heart failure). Symptoms of 2nd-degree or higher AV block, & of atrial fibrillation & flutter. Associated w/ dizziness which could increase occurrence of accidental injury or falls. DRESS. Risks in patients w/ phenylketonuria. Combination w/ products known to be associated w/ PR prolongation. Not recommended in severe hepatic impairment. Pregnancy. Discontinue breastfeeding during treatment. Elderly.

Dizziness, headache; diplopia; nausea. Depression, confusional state, insomnia; balance disorder, abnormal coordination, memory impairment, cognitive disorder, somnolence, tremor, nystagmus, hypoesthesia, dysarthria, disturbance in attention, paraesthesia; blurred vision; vertigo, tinnitus; vomiting, constipation, flatulence, dyspepsia, dry mouth, diarrhoea; pruritus, rash; muscle spasms; gait disturbance, asthenia, fatigue, irritability, feeling drunk; fall, skin laceration, contusion.

Medicinal products known to be associated w/ PR prolongation (eg, carbamazepine, lamotrigine, eslicarbazepine, pregabalin), & class I antiarrhythmics.

Anticonvulsants

N03AX18 - lacosamide ; Belongs to the class of other antiepileptics.

Rx